Targeting Mek Induces Myeloma-cell Cytotoxicity and Inhibits Osteoclastogenesis.
From: The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. yu-tzu_tai@dfci.harvard.edu
Blood
- Publish Date: Sep 2007
- ISSN: 0006-4971
- Volume: 110
- Issue: 5
- Pages: 1656-63
- Medium: Print
- Language: English
- Citation (JAMA): Tai Yu-Tzu, Fulciniti Mariateresa, Hideshima Teru, et al. Targeting Mek Induces Myeloma-cell Cytotoxicity and Inhibits Osteoclastogenesis.. Blood Sep 2007;110:1656-63
Abstract
Activation of the extracellular signal-regulated kinase1/2 (ERK1/2) signaling cascade mediates human multiple myeloma (MM) growth and survival triggered by cytokines and adhesion to bone marrow stromal cells (BMSCs). Here, we examined the effect of AZD6244 (ARRY-142886), a novel and specific MEK1/2 inhibitor, on human MM cell growth in the bone marrow (BM) milieu. AZD6244 blocks constitutive and cytokine-stimulated ERK1/2 phosphorylation and inhibits proliferation and survival of human MM cell lines and patient MM cells, regardless of sensitivity to conventional chemotherapy. Importantly, AZD6244 (200 nM) induces apoptosis in patient MM cells, even in the presence of exogenous interleukin-6 or BMSCs associated with triggering of caspase 3 activity. AZD6244 sensitizes MM cells to both conventional (dexamethasone) and novel (perifosine, lenalidomide, and bortezomib) therapies. AZD6244 down-regulates the expression/secretion of osteoclast (OC)-activating factors from MM cells and inhibits in vitro differentiation of MM patient PBMCs to OCs induced by ligand for receptor activator of NF-kappaB (RANKL) and macrophage-colony stimulating factor (M-CSF). Finally, AZD6244 inhibits tumor growth and prolongs survival in vivo in a human plasmacytoma xenograft model. Taken together, these results show that AZD6244 targets both MM cells and OCs in the BM microenvironment, providing the preclinical framework for clinical trials to improve patient outcome in MM.
Mesh Headings (Keywords): Animals, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Bone Marrow Cells, Boronic Acids, Cell Adhesion, Cell Differentiation, Cell Proliferation, Cell Survival, Cytotoxins, Dexamethasone, Dose-Response Relationship, Drug, Interleukin-6, Ligands, MAP Kinase Kinase 1, MAP Kinase Kinase 2, MAP Kinase Signaling System, Macrophage Colony-Stimulating Factor, Mice, Mice, SCID, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Multiple Myeloma, Neoplasm Transplantation, Osteoclasts, Phosphorylcholine, Pyrazines, RANK Ligand, Stromal Cells, Thalidomide, Transplantation, Heterologous, Tumor Cells, Cultured, Xenograft Model Antitumor Assays
Check for Full Text / PubMed Unique Identifier (PMID): 17510321
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.